Table 1.

Clinical characteristics of subjects, HTN history and treatment, and home BP measurements (three measurements morning and evening, three consecutive days)

CharacteristicsHS (n=82)Het (n=81)GS (n=79)ANOVA P Value
Whole population
 Age, yr40.3 [28.1; 56.1]43.2 [25.7; 58.4]39 [27.7; 51.1]0.85
 BMI, kg/m223.8 [21.5; 25.4]23.2 [21.6; 25.7]23.8 [20.7; 26.5]0.89
 Women/men (ratio)44/38 (0.53)46/35 (0.57)42/37 (0.53)0.9
 Past history of HTN066
 Newly discovered HTN735
 White-coat HTN382
 Antihypertensive drugs
  Potassium-sparing diuretics030
  ACE inhibitors031
  ARB031
  β-blockers044
  Calcium channel blockers02
 Home BP
  SBP, mm Hg118 [112; 127]a116 [108; 127]113 [107; 121]0.04
  Diastolic BP, mm Hg71 [66; 76]70 [64; 76]70 [66; 74]0.82
  HR, bpm70 [63; 77]b69 [64; 77]a74 [69; 79]0.005
Subpopulations(n=82)(n=74)(n=49)
 Antihypertensive drugs000
 Home BP
  SBP, mm Hg118 [112; 127]116 [108; 125]113 [107; 124]0.13
  Diastolic BP, mm Hg71 [66; 76]69 [64; 76]69 [66; 72]0.59
  HR, bpm70 [63; 77]a69 [63; 79]a75 [69; 79]0.009
  • Whole population analyses: all participants were included in the study. Subpopulation: hypertensive or diabetic participants were excluded as were patients with GS treated with potassium-sparing diuretics. Data are presented as median [IQR]. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.

  • For HS or Het versus patients with GS.

  • a P<0.05.

  • b P<0.001.